where we participated…

Medicinal Chemistry

„Synthesis of a tubugi-1-toxin conjugate by a modulizable disulfide linker system with a neuropeptide Y analogue showing selectivity for hY1R-overexpressing tumor cells”, Beilstein J. Org. Chem. 2019, 15, 96–105. doi:10.3762/bjoc.15.1

“Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection”, Frontiers in pharmacology 2018, 9, 296

„A cleavable cytolysin–neuropeptide Y bioconjugate enables specific drug delivery and demonstrates intracellular mode of action”, Journal of Controlled Release 2015, 209, 170-178

“NPY1 receptor specific peptide-drug-conjugates as novel treatment for metastatic breast cancer”, Cancer Research 2015, 75(15) Supplement Pages 1745-1745

“Combinatorial chemistry by ant colony optimization”, Future medicinal chemistry 2014, 6, 267-280

„On the industrial applications of MCRs: molecular diversity in drug discovery and generic drug synthesis.”, Molecular Diversity2010 Aug;14(3):513-22

“Isoquinolin-1-one inhibitors of the MDM2-p53 interaction.”, ChemMedChem 2008 3(7), 1118-28.

“Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.”, Mol. Cancer Ther. 2007, 6(8):2220-9.

“In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.” , Mol. Cancer Ther. 2007, 6, 898-906.

“Initial Design and Synthesis of Conformationally Restricted and Pharmacophore-Based Scaffold Hopping Analogs of a Ras Pathway Modulator and Evaluation of Their MAPK Inhibitory Activities”, Letters in Drug Design & Discovery 2006, 3, 625-630.

“Molecular Basis for the Inhibition of p53 by Mdmx”, Cell Cycle 2007, 6:19, 2386-2392.

“Chemistry for Chemical Genomics.” in “Chemical Genomics: Reviews and Protocols”, E.D. Zanders (ed.), Humana Press, Totowa, New Jersey, 2005.

“Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator.”, Bioorg. Med. Chem. Lett. 2004, 14, 3957-3962.


“Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.”, Cell Cycle 2014, Jun 23;13(14).

“A two-hybrid approach to identify inhibitors of the RAS-RAF interaction.”, The Enzymes, Vol. 33, Burlington: Academic Press 2013, pp. 213-248.

“Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells.”, J. Mol Signal. 2010 Feb 23;5(1):2

“Ras-driven transformation of human nestin-positive pancreatic epithelial cells..”, Methods Enzymol. 2008, 439, 451-65.

“Selective Raf inhibition in cancer therapy.”, Expert Opin. Ther. Targets 2007, 11(12),1587-1609.

“K-Ras Promotes Growth Transformation and Invasion of Immortalized Human Pancreatic Cells by Raf and Phosphatidylinositol 3-Kinase Signaling.” , Cancer Res. 2007, 67, 2098-2106.

“Development of a Yeast Two-hybrid Screen for Selection of Human Ras-Raf Protein Interaction Inhibitors.” in “Chemical Genomics: Reviews and Protocols” E.D. Zanders (ed.), Humana Press, Totowa, New Jersey, 2005.

“Fractal Box Counting Applied to Structure-Property Relationships” L. Weber, M. Almstetter, M. Cappi, T. Fuchs, S. Hess, K. Illgen, A. Treml, P. Zegar, Medicinal Chemistry Conference, Istambul 2004.

“Combinatorial chemistry: Evolution of design and design of evolution”, Mark Bradley, Lutz Weber (eds), Current Opinion in Chemical Biology, Volume 4, Issue 3, 1 June 2000, Pages 255-256

“Protein-Protein Interactions: A Molecular Cloning Manual”, Erica A. Golemis, Peter D. Adams (eds), Cold Spring Harbor Laboratory Press 2005.

“Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells”, PNAS 2002.

Medicinal Chemistry Datasets

Data set of 16896 Ugi MCR reaction products, tested against thrombin, factor Xa, uPA, Tryptase and Chymotrypsin.

FractalBoxes and FractalData for SAR please ask and we will send you the data.

Consent Management Platform by Real Cookie Banner